共 31 条
- [1] EFFICACY AND PHARMACOKINETICS OF ORAL TESTOSTERONE (LPCN 1021) IN HYPOGONADAL MEN JOURNAL OF SEXUAL MEDICINE, 2016, 13 (05): : S14 - S14
- [2] EFFICACY AND PHARMACOKINETICS OF LPCN 1021, A NOVEL ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT), IN HYPOGONADAL MEN: STUDY OF ANDROGEN REPLACEMENT (SOAR) JOURNAL OF UROLOGY, 2015, 193 (04): : E773 - E773
- [3] HYPOGONADAL MEN WITH SEXUAL FUNCTION DISORDER BENEFIT FROM LPCN 1021 (ORAL TESTOSTERONE) - SOAR (STUDY OF ANDROGEN REPLACEMENT) TRIAL JOURNAL OF UROLOGY, 2016, 195 (04): : E1010 - E1011
- [4] Dietary Fat Modulates the Testosterone Pharmacokinetics of a New Self-Emulsifying Formulation of Oral Testosterone Undecanoate in Hypogonadal Men JOURNAL OF ANDROLOGY, 2012, 33 (06): : 1282 - 1290
- [5] SALIVA AND SERUM TESTOSTERONE FOLLOWING ORAL TESTOSTERONE UNDECANOATE ADMINISTRATION IN NORMAL AND HYPOGONADAL MEN ACTA ENDOCRINOLOGICA, 1983, 102 (03): : 456 - 462
- [8] Effects of the oral testosterone undecanoate Kyzatrex™ on ambulatory blood pressure in hypogonadal men JOURNAL OF CLINICAL HYPERTENSION, 2021, 23 (07): : 1420 - 1430
- [10] LONG-TERM SAFETY AND TOLERABILITY OF ORAL TESTOSTERONE (LPCN 1021) IN HYPOGONADAL MEN: RESULTS FROM THE 52-WEEK PHASE 3 STUDY JOURNAL OF UROLOGY, 2016, 195 (04): : E1187 - E1188